Terrence Metz1, Amer Heider2, Ranjith Vellody3, Marcus D Jarboe4,5, Joseph J Gemmete5, Jason J Grove5, Ethan A Smith5, Rajen Mody6, Erika A Newman4, Jonathan R Dillman7. 1. Department of Radiology, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA. 2. Department of Pathology, C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 3. Department of Radiology, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 4. Section of Pediatric Surgery, C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 5. Department of Radiology, C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 6. Department of Pediatrics, Division of Pediatric Hematology/Oncology, C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI, USA. 7. Department of Radiology,Cincinnati Children's Hospital Medical Center,, University of Cincinnati College of Medicine, 3333 Burnet Ave., ML 5031, Cincinnati, OH, 45229-3039, USA. jonathan.dillman@cchmc.org.
Abstract
BACKGROUND: A paucity of literature describes the use of imaged-guided percutaneous core needle biopsy for the diagnosis and characterization of pediatric soft-tissue masses and lesions. OBJECTIVE: To retrospectively determine whether image-guided percutaneous core needle biopsy is adequate for diagnosing and characterizing benign and malignant pediatric soft-tissue masses and lesions. MATERIALS AND METHODS: We identified children (≤18 years old) who underwent US- or CT-guided percutaneous core needle biopsy of a soft-tissue mass or other lesion between January 2012 and March 2014. Using medical records, we documented the following data: age and gender, site of the mass or lesion, size and number of biopsy specimens, whether the biopsy procedure was diagnostic, whether sufficient tissue was obtained for necessary ancillary testing (e.g., cytogenetic evaluation), and whether there was a procedural complication within 1 week. RESULTS: One hundred eight soft-tissue masses or lesions were biopsied under imaging guidance in 84 children; 39 (46%) were girls. Mean age ± standard deviation (SD) was 12.1 ± 5.1 years (range 6 months to 18 years). Of these procedures, 105/108 (97%) were diagnostic; 82/108 (76%) were US-guided; 87/108 (81%) were performed using a 17-gauge introducer needle/18-gauge biopsy instrument. The mean number ± SD of core needle biopsy specimens obtained was 8.9 ± 5.0. For newly diagnosed malignancies, adequate tissue was obtained for ancillary testing in 28/30 (93%) masses. One minor complication was documented. CONCLUSION: Image-guided percutaneous core needle biopsy of pediatric soft-tissue masses is safe, has a high diagnostic rate, and provides sufficient tissue for ancillary testing.
BACKGROUND: A paucity of literature describes the use of imaged-guided percutaneous core needle biopsy for the diagnosis and characterization of pediatric soft-tissue masses and lesions. OBJECTIVE: To retrospectively determine whether image-guided percutaneous core needle biopsy is adequate for diagnosing and characterizing benign and malignant pediatric soft-tissue masses and lesions. MATERIALS AND METHODS: We identified children (≤18 years old) who underwent US- or CT-guided percutaneous core needle biopsy of a soft-tissue mass or other lesion between January 2012 and March 2014. Using medical records, we documented the following data: age and gender, site of the mass or lesion, size and number of biopsy specimens, whether the biopsy procedure was diagnostic, whether sufficient tissue was obtained for necessary ancillary testing (e.g., cytogenetic evaluation), and whether there was a procedural complication within 1 week. RESULTS: One hundred eight soft-tissue masses or lesions were biopsied under imaging guidance in 84 children; 39 (46%) were girls. Mean age ± standard deviation (SD) was 12.1 ± 5.1 years (range 6 months to 18 years). Of these procedures, 105/108 (97%) were diagnostic; 82/108 (76%) were US-guided; 87/108 (81%) were performed using a 17-gauge introducer needle/18-gauge biopsy instrument. The mean number ± SD of core needle biopsy specimens obtained was 8.9 ± 5.0. For newly diagnosed malignancies, adequate tissue was obtained for ancillary testing in 28/30 (93%) masses. One minor complication was documented. CONCLUSION: Image-guided percutaneous core needle biopsy of pediatric soft-tissue masses is safe, has a high diagnostic rate, and provides sufficient tissue for ancillary testing.
Authors: M Sklair-Levy; P D Lebensart; Y H Applbaum; N Ramu; A Freeman; D Gozal; E Gross; Y Sherman; J Bar-Ziv; E Libson Journal: Pediatr Radiol Date: 2001-10
Authors: Kevin M Garrett; Christine E Fuller; Victor M Santana; Stephen J Shochat; Fredric A Hoffer Journal: Cancer Date: 2005-08-01 Impact factor: 6.860
Authors: Courtney L Devin; Erin A Teeple; Allison F Linden; Renee C Gresh; Loren Berman Journal: Pediatr Surg Int Date: 2021-06-20 Impact factor: 1.827
Authors: Tatjana Gruber-Rouh; Axel Thalhammer; Thomas Klingebiel; Nour-Eldin A Nour-Eldin; Thomas J Vogl; Katrin Eichler; Nagy Naguib; Martin Beeres Journal: Ital J Pediatr Date: 2017-01-06 Impact factor: 2.638
Authors: Philippa Meershoek; Nynke S van den Berg; Jacob Lutjeboer; Mark C Burgmans; Rutger W van der Meer; Catharina S P van Rijswijk; Matthias N van Oosterom; Arian R van Erkel; Fijs W B van Leeuwen Journal: Eur J Radiol Open Date: 2021-07-08